ArticleInternational urology and nephrology2001
CD44 standard form expression as a predictor of progression in high risk superficial bladder tumors.
Article in International urology and nephrology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 27 citations in OpenAlex.
- Study on Molecular Information Intelligent Diagnosis and Treatment of Bladder Cancer on Pathological Tissue Image.Frontiers in medicine · 2022Article
- Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?Oncotarget · 2017Review
- New and promising strategies in the management of bladder cancer.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2015Review
- CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis.Human pathology · 2013Article
- CD44 expression in intraoral salivary ductal papillomas and oral papillary squamous cell carcinoma.Head and neck pathology · 2013Article
- Immunohistochemical expression of CD44s in human neuroblastic tumors: Moroccan experience and highlights on current data.Diagnostic pathology · 2013Article
- The androgen receptor and stem cell pathways in prostate and bladder cancers (review).International journal of oncology · 2012Review
- Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis.Cancer · 2011Article
- Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion.Cellular signalling · 2009Review
- Hyaluronan and hyaluronidase in genitourinary tumors.Frontiers in bioscience : a journal and virtual library · 2008Review
- Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.Journal of cancer research and clinical oncology · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of this study was to assess the significance of the standard CD44 adhesion molecule expression in predicting progression of high risk superficial bladder carcinoma in the short term.
methodsSixty-six patients (51 males and 15 females, aged 27 to 89 years (mean 64.75 years) with primary superficial transitional cell bladder cancer initially treated with transurethral resection (TURBT) were enrolled in the study. Only pTa/pT1 grade 2 multiple tumors as well as all grade 3 tumors were included in this study. All tumor samples obtained after the resection were immunohistochemically evaluated for the expression of the CD44 standard molecule. Fifty eight patients remained during the follow up period which ranged from 3 to 36 months (mean 11.8 months). Tumor progression in the short term was considered as the critical end point of interest in this study. The prognostic significance of tumor stage, grade, presence of carcinoma-in-situ (CIS) and expression of CD44 in determining the risk for progression, was studied with both univariate (log rank test) and multivariate (Cox proportional hazards) methods of analysis.
resultsKaplan-Meier survival curves indicated that a shorter median progression-free survival is expected for those patients with G3 bladder tumors (p = 0.0055), concomitant CIS (p = 0.0051), and loss of expression of CD44 (p = 0.0015), whereas a similar association with stage was not detected (p = 0.5793). The cox regression multivariate analysis did not yield a significant result for any of the studied parameters therefore no one of the factors taken into account can serve as an independent predictor of progression in superficial bladder cancer in the short term.
conclusionThe immunohistochemically detectable loss of the expression of CD44 standard form from superficial bladder tumor samples may be, complementary to the established prognostic factors, a useful predictor of tumor progression in the short term.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.